BPC 157 cycle lengths get quoted with impressive confidence, and every one of them is borrowed from a drug class this peptide has nothing in common with. Cycling is a concept from anabolic steroid practice. It exists for specific reasons, and none of those reasons has been shown to apply here.
The vendor we point lifters to
BPC-157 from Ascension Peptides
Independently assayed material, dispatched from the US. Both drop by half with the code below.
The Wolverine Stack is BPC-157 10 mg combined with TB-500 10 mg in one vial, so its per-mg figure spans both compounds. Quantity tiers take 3%, 5% or 10% off the list price; free shipping starts at $250.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 19, 2026.
That does not mean using it continuously is wise. It means the reasoning people import is the wrong reasoning, and swapping it for the right one changes what the question is.
Where the cycle idea came from in the first place
Anabolic steroid users cycle because continuous use suppresses the body's own testosterone production, and time off is an attempt to let that recover. Add receptor level adaptation with prolonged exposure, cumulative effects on lipids, blood pressure and other organ systems, and for tested athletes the practicalities of detection, and a structure of on periods and off periods follows logically from the pharmacology.
Every one of those reasons is specific to hormones acting on nuclear receptors. Transfer the structure to a fifteen amino acid peptide with no described hormonal activity and the structure survives while the logic underneath it does not.
Why a BPC 157 cycle has no rationale to copy
Take the reasons one at a time. There is no evidence that this compound suppresses any hormonal axis, so there is nothing for time off to restore. There is no published evidence of tolerance or receptor downregulation with continued exposure in any species, so an off period has no described function. There is no detection advantage available, because in sport it falls under the category covering non approved substances, which is prohibited at all times rather than in competition only.
Notice what these statements have in common. They are all statements about absent evidence, not demonstrated absence. Nobody has run the study that would show hormonal effects if they existed, and nobody has run the study that would show tolerance. The correct conclusion is that the steroid framework has no support here, not that continuous use has been shown to be fine.
What the animal studies used instead: healing windows
The published research does not contain cycles. It contains treatment windows tied to injuries. A rat with a transected Achilles tendon, damaged knee ligament or crushed skeletal muscle was treated for the period over which that injury heals, then the tissue was assessed against untreated controls. Duration was a property of the injury model, not a schedule chosen for the compound.
That is a genuinely different concept, and it happens to be the more sensible one. If the animal findings translate at all, the sane framing is a defined repair problem with a defined endpoint rather than an ongoing regimen. The registered human trials are built the same way: NCT07437547 is a Phase 2 study in 120 participants with acute hamstring strain, recruiting, and NCT07803250 is a Phase 1 study in 30 participants concerning recovery after rotator cuff repair, not yet recruiting. Human trials exist and are registered, and none has published efficacy results.
It is also worth noting what this compound is, since the category it gets filed under does most of the misleading. It is a synthetic pentadecapeptide based on a partial sequence of a protein found in gastric juice, and its efficacy literature is overwhelmingly rat and cell culture work covering tendon, ligament, muscle and gut outcomes. Vendors shelve it beside growth hormone secretagogues and other physique compounds, and proximity on a product page becomes, in a reader's head, similarity of effect. It is not similar.
The anabolic question, answered without hedging
Readers on this site usually arrive at the cycle article carrying an assumption, so it is worth stating flatly. This compound is not anabolic. It has no established action on the myostatin pathway. It is not described as stimulating muscle protein synthesis. There is no hypertrophy dataset and no performance dataset in humans. Cycling it around a training block in the way someone might cycle an anabolic agent has no mechanistic basis at all.
The one finding that fuels the confusion is worth naming precisely. In cultured rat tendon fibroblasts, growth hormone receptor expression increased. That is a change in what connective tissue cells in a dish display, which supports a local repair story. It is not systemic growth hormone release, and it says nothing about skeletal muscle.
The plausible link to lean mass is indirect and unproven: connective tissue injuries cost training time, lost training time costs muscle, and older lifters accumulate those interruptions faster because tendon adapts and turns over more slowly than the muscle pulling on it. If repair were demonstrated in humans, the body composition benefit would show up as continuity across years, not as anything a cycle length could be planned around.
What does argue for limiting exposure
Dropping the steroid rationale does not leave nothing. It leaves a better argument, which is uncertainty.
There is no published long term human safety data for this compound. No marketing authorisation exists from the FDA, the EMA or the MHRA, so no regulator has reviewed a dossier. Rat toxicology from the original research groups reported no observed toxicity at the amounts studied, over observation windows that were short compared with how long people actually use unregulated products. The most consistently reported mechanism in the animal work concerns blood vessel formation, which raises an unresolved theoretical question about other tissue that depends on new vessels, with no human data on either side.
There is a training specific risk in open ended use as well. If an area feels better, whether from a real effect or from expectation, the pull is to load it again sooner. Tendon repair runs on a timeline set by tissue biology, and feeling ready is a poor proxy for being ready. An indefinite regimen quietly encourages training through something that needed a few more weeks, which is the ordinary route by which a manageable strain becomes a chronic one.
Supply adds the rest. Sold as a research chemical, identity, purity, concentration and sterility rest on the seller's paperwork, and a certificate of analysis usually describes a batch rather than the vial in hand. Longer exposure means more batches, more suppliers and more chances for one of them to be wrong.
Put together, the case for keeping any use short and tied to a specific problem rests on how little is known, which is a sturdier argument than a borrowed schedule.
Related reading on this compound: the benefit claims graded by organism, what the published protocols ran, what is known about side effects.
What people ask about cycling
Do I need time off between uses?
No published evidence establishes a need, because nothing has shown hormonal suppression or tolerance. Equally, nothing establishes that continuous use is safe, since long term human data does not exist.
Is there a standard cycle length?
No. There is no approved use and no published human efficacy result, so any specific length in circulation is convention rather than evidence.
Should I run it alongside a bulk?
There is no reason to expect a body composition effect. The compound is not anabolic and no study in any species used muscle size or lean mass as an outcome.
Does it need post cycle therapy?
Post cycle therapy addresses suppression of natural hormone production. No hormonal suppression has been described here, so the concept does not transfer.
Is longer better for a stubborn tendon?
Unknown. Dose and duration response for tendon outcomes has been examined only in rats and cell culture, and those relationships have not been established in humans.
Would a positive trial result settle cycle length?
Only for the injury and exposure that trial used. A hamstring strain result would not generate a general schedule, and it would say nothing about training or body composition use.
Steroid cycle logic set against this peptide
| Reason cycles exist for anabolic steroids | Does it apply here | What that rests on |
|---|---|---|
| Natural testosterone production is suppressed and needs to recover | No described hormonal activity | No evidence in any species |
| Receptors adapt with continuous exposure | Tolerance has not been described | No evidence in any species |
| Cumulative strain on lipids, blood pressure and organs | Not described, and not studied over time | Rat toxicology, short windows |
| Timing use around testing | No advantage, prohibited at all times in sport | Sport regulation |
| Diminishing returns on muscle gain | No muscle outcome exists to diminish | No study in any organism used growth as an outcome |
| Matching exposure to a healing timeline | This is the framing the research actually uses | Rat injury models, human trials registered without results |
The final row is the one to take away. The research treats this as a repair intervention with an endpoint, not a compound to run in blocks around training. Anyone selling a cycle chart is selling a structure the literature never used.